Royalty Pharma Q3 2022 Earnings Report
Key Takeaways
Royalty Pharma reported a 15% increase in net cash provided by operating activities, reaching $539 million, and a 2% increase in Adjusted Cash Receipts, totaling $597 million. The company announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments. Royalty Pharma increased its full-year 2022 guidance for Adjusted Cash Receipts to $2,750 to $2,800 million.
Net cash provided by operating activities (GAAP) increased 15% to $539 million.
Adjusted Cash Receipts increased 2% to $597 million, driven by strong portfolio performance and the acquisition of royalties on Trelegy.
Adjusted EBITDA grew 3% to $548 million.
Adjusted Cash Flow increased 26% to $441 million.
Royalty Pharma
Royalty Pharma
Forward Guidance
Royalty Pharma anticipates full-year 2022 Adjusted Cash Receipts to be between $2,750 million and $2,800 million. The guidance reflects an estimated foreign exchange impact of approximately -3% to -4% for full-year 2022 year/year Adjusted Cash Receipts growth, assuming current exchange rates prevail for the balance of 2022.